New drugs: Etravirine, sinecatechins, and desvenlafaxine succinate.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
Campoli
Katie E
KE
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002392:Catechin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003218:Condylomata Acuminata / Q000188:drug therapy; D003511:Cyclohexanols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy; D000069468:Desvenlafaxine Succinate; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D009570:Nitriles; D008517:Phytotherapy; D011724:Pyridazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines
D019380:Anti-HIV Agents; D000928:Antidepressive Agents; D003511:Cyclohexanols; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; C527126:green tea extract polyphenone E; C451734:etravirine; D002392:Catechin; D000069468:Desvenlafaxine Succinate